We leverage our “omics” platforms and multi-modal patient data to generate unique insights into the biology of immune mediated diseases.

Gaining a deep patient level understanding of the cellular and immune pathway central to the pathology of autoimmunity and inflammatory diseases allows us to rapidly advance programs from concept toward clinical trials.

Current commercial therapeutic approaches used in the treatment of patients with immune mediated diseases, target mainly the broad neutralization of cytokines. This general immune suppression carries unwanted side effects for many patients. A deeper more thorough understanding the cell types and pathways that give rise to the pathology allows for the development of therapeutic programs that can precisely target and eliminate or suppress these pathogenic cell and pathways.